NCT04792463
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: DNA damage repair mutations
Breast Cancer Tissue:
Recruitment Status: Recruiting
Drug Category: Other
Key Eligibility Criteria:
Gender: All
Age: Child, Adult, Older Adult
Location of Metastases:
Additional Notes: Patient or family member must have a BAP1 hereditary mutation or variant of uncertain significance
Exclusions:
https://ClinicalTrials.gov/show/NCT04792463